European Venous Registry (EVeR)

An international registry of data on the treatments and outcomes of people with deep venous disease, designed to generate scientific evidence to improve clinical decision-making.

In Collaboration with

Why Join EVeR

Access unique resources, research opportunities, and a supportive clinical community.

Benchmarking Data

Compare your outcomes with centres across Europe.

Research Support

A data repository to enhance clinical research.

Clinical Insights

Improve patient care with evidence-based guidance.

Benefits of joining for medical centres

Medical centres in Europe treating deep venous diseases and contributing at least 5 cases per year to the registry enjoy these benefits:

If you experience any technical issues, please contact the EVeR Registry support team at +44 20 8949 8999 or national-support@e-dendrite.com.

Please provide a detailed description of the issue, including any error messages, and copy in info@esvs.org.

Industry Partners

Join our registry today to access annual benchmarking reports and more. Calling all medical device manufacturers for stents, IVUS, CDT, and non-invasive treatments! Become an Industry Partner and optimise your device performance.

Monitoring

Monitor and evaluate the quality of healthcare delivered

Regulations

Meet your regulatory requirements

Research & Treatment

Advance research and science for the benefit of patients

Founding Industry Partners

Industry Partner

Associate Industry Partners

Quotes from experts

Our department has a long experience treating deep venous disorders, with 25 years after the first venous stenting and more a consolidated program of recanalization in acute iliofemoral DVT.
Our Achilles heel has been the appropriate registry and analysis of that work and we
received with excitement the possibility to join other European Centres in this mission of
gathering high quality data in the EVeR!
Our experience with the internal administrative process wasn’t easy because it involved
several Hospital committees (scientific, ethical and data protection) with some other
bureaucratic obstacles on the way.
Our main assets during this process were our will to join this venture and the robust
documentation provided by the EVeR Organization.
We added our first patient to the EVeRegistry on the last week of August and found the
navigation through the registry to be very user friendly and the requested data to be very
inline to the usual clinical workload of our department.”

Santo António's Local Unit of Health

As a Professor of Tissue Viability and Wound Care, I strongly support the inclusion of conservative treatments and non-surgical specialities in the EVeR registry. Chronic wounds and tissue complications are often key indicators of deep venous disease progression and profoundly influence patient outcomes. By involving disciplines like wound care and haematology, we ensure the registry captures the full patient journey, not just procedural interventions. This holistic perspective is essential for generating meaningful real-world data, reducing practice variation, and driving improvements in care quality across all specialities involved in venous health.

Professor Sebastian Probst

Tissue Viability and Wound Care, Geneva School of Health Sciences

MUMC Maastricht has always been a frontier when it comes to the treatment of patients with deep venous disease both conservatively and interventional. Our team of vascular surgeons, interventional radiologist and internist work closely together to navigate care and research. In this day and age creating evidence for interventional procedures that already have been widely accepted is difficult. As an alternative the European registry can provide inside in our own data as well as contribute to a wider acceptance and understanding in treating patients with acute and chronic deep venous thromboses. It was relatively easy to get approval from the board and the local METC so I would advise all centers that are treating these patients to enter the registry. Data entry is straight forward and does not take up a lot of extra time. Most of the questionnaires are already standard practice in our follow up and the calculations are made by the registry itself.

Join us on the road to optimal treatment of patients with deep venous disease!

Greetings from MUMC.

Dr A Ten Cate, Dr K. Winckers, Prof M. de Haan, Drs R Brans, Drs J Jongkind, drs J van Laanen, drs A. Prent

Maastricht UMC

Navigation Tutorials

Step-by-step video guides to help you navigate and manage the registry with confidence and ease.

Frequently Asked Questions

Find quick answers to common questions about the European Venous Registry.

FAQ

Who can participate in EVeR?

Hospitals, research institutions, and clinical centres in Europe specialising in vascular medicine and thromboembolic diseases are eligible to participate.

Centres must establish the necessary legal and operational agreements with the registry sponsor, the European Society for Vascular Surgery (ESVS). Prior to participating in the registry and submitting data, centres are also required to obtain ethical approval from their local or national ethics committees. Additionally, written informed consent must be obtained from each patient before any data can be collected or processed. Without patient consent, inclusion in the registry is not permitted.

How do I enter patient data into the registry?

Data can be entered through the secure online platform provided to participating centres. Each centre will receive login credentials and training materials.

Is extensive medical history required?

No, only anticoagulation status and core clinical information are needed.

Are non-procedural patients (e.g. those managed conservatively for DVT) eligible?

Yes, these cases are essential for future analysis and benchmarking.

Is there reimbursement for participating centres?

Yes. Centres receive €150 per patient, distributed over different follow-up stages:

€50 after pre-operative, procedural, and 3-month follow-up data submission.
€50 after 1-year, 2-year, and 3-year follow-up data submission.
€50 after 4-year and 5-year follow-up data submission.

However, the EVeR Registry does not provide additional reimbursement for site setup, administrative overheads, or other indirect costs associated with participation.

Reimbursement is processed monthly upon receipt of:

An invoice from the participating centre.
A patient consent form (if applicable) for the first stage of data submission.

Can patients be co-enrolled in other trials?

Yes, subject to local trial policies.

Can non-physicians with GCP training obtain consent?

Yes, if they meet local training requirements.

What governance structure oversees the Registry?

EVeR Registry is governed by the European Society for Vascular Surgery (ESVS) Executive Committee, which approves the project plan, business model, and budget. The Steering Committee oversees the design, data monitoring, and stakeholder management, while various advisory boards provide feedback and recommendations.

How is patient data protected in the Registry?

All data is encrypted and stored on secure servers compliant with GDPR and other relevant data protection regulations. Only authorised personnel have access to the data.

The registry complies with GDPR and other legal requirements. Data is pseudonymised and securely stored within an ISO 27001-accredited EU data centre provided by Dendrite. Regular audits and security assessments ensure compliance with NHS Information Governance and Cyber Essentials Plus certification.

Can my institution access and download the data we have submitted?

To ensure the security and integrity of the registry, different user roles are assigned with specific access levels. Only the physician, as the official record owner, has permission to export data from the registry portal.

Designated delegates (e.g., research nurses) can enter data on behalf of the physician but cannot download or export it.

What steps must researchers follow to access EVeR Registry data?

To request access, researchers must:

Submit an application to the Steering Committee, including:
- A CV demonstrating research capability.
- A standardised proforma outlining study objectives, methodology, and ethical considerations.
Obtain ethical approval (if required).
Sign a Data Sharing Agreement, confirming:
- Compliance with GDPR & data security protocols.
- Use of data only for the approved research purpose.
- Commitment to responsible data handling.
Submit official certification of ethics approval (where required).

What criteria are used to evaluate research applications?

The Steering Committee assesses applications based on:

Alignment with the registry’s scientific objectives.
Scientific integrity and feasibility of the study.
Compliance with GDPR and ethical standards.
Whether appropriate ethical approval has been obtained or is required.

Do researchers need ethical approval for their study?

In some countries, generic approval covers all research using the EVeR Registry, and no additional ethics application is needed.

If generic approval does not apply in a particular country or for a specific type of study, the researcher must obtain individual ethics approval from a recognised ethics review board.

Additionally, organisations where the research is conducted (such as NHS sites) must grant R&D permission before researchers can proceed with studies using the database.